Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?

Jan 11 2018

• By Derrick Gingery

RulesRegulationsBooks_1200x675

Related Content

FDA Exploring Whether Public Shaming Can Stop REMS Abuses

Jul 19 2017

US FDA's Benefit/Risk Framework Gets High Marks But Could Be Improved

Sep 20 2017

FDA To Use New Discipline Review Letters In Communicating ANDA Deficiencies To Generic Drugmakers

Dec 28 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Additional Topics

United States Generic Drugs Drug Review Regulation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window